Overview
IDXX market data
Price History
IDXX price chart
Valuation & Profitability
- P/E (TTM)
- 39.00 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $13.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.55 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 25.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $518.55 – $769.98 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $44.4B · P/B 33.65 · P/S 9.76.
Company News
Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710Benzinga · Aug 11, 2026, 1:51 PM
IDEXX Announces Launch Of Catalyst proBNP Test For Assessing Heart Disease In Cats And Dogs, Available In North America Beginning October 2026Benzinga · Aug 11, 2026, 11:09 AM
UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670Benzinga · Aug 5, 2026, 8:27 PM
Citigroup Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670Benzinga · Aug 5, 2026, 6:58 PM
Why Is IDEXX Laboratories Stock Gaining Tuesday?Benzinga · Aug 4, 2026, 3:39 PM
IDEXX Laboratories Q2 2026 Earnings Call TranscriptBenzinga · Aug 4, 2026, 1:35 PM
IDEXX Laboratories shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 GAAP EPS guidance above estimates.Benzinga · Aug 4, 2026, 11:46 AM
8-K filing — IDEXX LABORATORIES INC /DE (IDXX)SEC EDGAR · Aug 4, 2026, 10:32 AM
IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B EstBenzinga · Aug 4, 2026, 10:31 AM
IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B EstimateBenzinga · Aug 4, 2026, 10:30 AM